๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
4DMedical Limited (ASX:4DX)
Australia flag Australia ยท Delayed Price ยท Currency is AUD
2.120
-0.040 (-1.85%)
Nov 23, 2026, 10:10 AM AEDT
โ† View all transcripts

Bell Potter Healthcare Conference

Nov 16, 2026

Summary

CT:VQ is gaining adoption as a contrast-free functional lung imaging option, with Cleveland Clinic planning a full shift from nuclear VQ. CLEAR could open the larger CTPA market; management expects strong revenue growth through 2027 and break-even around 2028.

John Hester
Senior Analyst, Bell Potter Securities

It's now my pleasure to welcome back to the conference the CEO of 4DMedical, Dr. Andreas Fouras. For those not familiar with the company, 4DMedical has developed a product suite designed to assist pulmonary physicians in their diagnosis and management of patients with acute respiratory disease, including the likes of emphysema, asthma, and a range of other conditions. In the last 12 months, the company has made enormous progress with commercialization, particularly in the U.S.

Led by the rollout of its CT:VQ exam, which has gained very encouraging uptake from leading academic medical centers in the U.S., namely at Stanford University and the University of Chicago. On the back of that success, the company completed a highly successful capital raise earlier this year, and is now very well funded to accelerate these commercialization activities. With that backdrop, it's welcome to Andreas, and thank you for joining us. Andreas, good to see you.

Andreas Fouras
CEO, 4DMedical

Hi, John. Great to be here.

John Hester
Senior Analyst, Bell Potter Securities

Yeah, it's been a really exciting year. Congratulations on all the progress that you've made.

Andreas Fouras
CEO, 4DMedical

Yeah, thanks. I really appreciate that. We've been investing, as you know, John, for over a decade in terms of building the foundations. I think now it's great that, I guess, the building works have gotten above ground and-

John Hester
Senior Analyst, Bell Potter Securities

Yeah

Andreas Fouras
CEO, 4DMedical

some of it's more visible to everybody else.

John Hester
Senior Analyst, Bell Potter Securities

Yeah, that's for sure. Let's jump into it, Andreas, and let's start the conversation with a discussion around your CT:VQ product, because that is the one that has got the market's attention, and it's been highly successful, created almost immediate market presence, and you've got some really good uptake by leading physicians. So, for those members of our audience who are not familiar with it, just explain it in a couple of sentences if you can. It's a complex product, but nevertheless, give us an overview of what CT:VQ is all about.

Andreas Fouras
CEO, 4DMedical

Sure. So, we're building upon our technology, our historical capability to measure airflow in the lungs. CT:VQ now adds to that this important capability that makes us the only company that has a product that can see airflow and blood flow in the lungs without the use of putting any exogenous contrast. So no inhalations, no injections into the body. Specifically, we're targeting right now displacing an existing test, the nuclear VQ test, and replacing that by just using a regular CT exam, hence the name CT:VQ.

John Hester
Senior Analyst, Bell Potter Securities

Okay. Andreas, just a little more explanation if you can. What are the fundamental differences between the technology that 4DMedical has and conventional imaging for management of patients with lung disease?

Andreas Fouras
CEO, 4DMedical

Yeah, so I think, if you kind of zoom out a bit, I think the thing that we bring is that the lungs have been left behind in this modernization of imaging where imaging 100 years ago, the very first X-ray, and for the 50, 60 years after that, was just about showing doctors a picture of how those parts of the body looked. Then, over the last 30, 40 years, technology has come out bringing, and we call that structure or anatomy. The last 30 or 40 years, function has become really the most important way that doctors have seen that they can really add value to their medical imaging.

For those of you who are just in your regular life, you might see on T.V. or you might get an MRI of your brain, and instead of just nowadays just showing a picture of your brain, it also has on top of that these colors that show which areas of the brain are firing. Or perhaps you or a loved one might have seen an ultrasound of a pregnant woman, and you see in that ultrasound now not just the picture of the fetus, but you also get on top of that color maps showing where the blood is flowing. This hasn't been coming to folks in the lungs, or not easily. What we've been able to do at 4DMedical is be able to do two big things all at the same time.

One of them is bring functional imaging to the lungs, so now doctors can see airflow and they can see blood flow. At the same time, we've done that without requiring what's been needed in those other areas. Doppler ultrasound that I was just talking about needed a new type of ultrasound device. fMRI needed a new type of MRI scanner. We're allowing doctors to use the existing infrastructure. There's already billions of dollars of CT scanners across Europe, Australia, and the U.S. Doctors can use those scanners. They can use them in the same way that they always have, and we can add on top of that capability, and do that also without needing them to have any injections into the body.

John Hester
Senior Analyst, Bell Potter Securities

Yeah, so it has been the first really big breakthrough in management of patients with these conditions for quite some time. CT:VQ was approved about 15 months or so ago in the U.S., and from almost the get-go, you got really good interest in the product from Stanford University and University of Chicago. Perhaps talk us through how those organizations have been using the product, and how that is progressing, because they are all on relatively short-term contracts. Some of those have been renewed and so on. Just talk us through how their progress has happened over the last 12 months or so.

Andreas Fouras
CEO, 4DMedical

Yeah, so you can imagine those very first sites, the first handful of sites to use the technology wanted us to do validation programs with them. So where they would get a few dozen scans, 50 scans perhaps. Cleveland Clinic wanted to see 100 scans. They wanted to go through, look at those scans, do reviews, have a whole bunch of doctors look at them, and just get comfortable that while it was FDA approved, and they saw that data, it was impressive, they wanted to see with their patients and their doctors that it added value to their practices. Over and again, across each of those AMCs that you mentioned, and including Cleveland Clinic, they have gone through, we have come out the other side of those validation programs, and they said, "Actually, you know what? We really do like it.

It does do what you told us it would do." In fact, there has been a couple of big statements that have come out from these AMCs that we are really proud of. They would be that Michigan has come out and said that, "If you use VQ as the screening technology for lung volume reduction surgeries, which is a $50,000 surgery, then you can increase success rates on those surgeries from 46% to 76%." I think while that is phenomenal, a generational kind of change in the success rate for a procedure like that. In some ways, commercially even more exciting is the word that came out from Cleveland Clinic where they said they can take a month off workup times for patients who are going in for procedures in their valve program.

That means reduction from about seven weeks down to about three weeks of workup time. That saves lots and lots of hours of doctors sitting around looking at scans, talking, what they call these multidisciplinary panels, very expensive thing to operate, and it is better for the patient. If you need a procedure, you want to get it done a month sooner, and the hospital saves a ton of money and loses less patients. I think we have gone through, we have had those validations, where they have looked at it, and then they have looked in more detail, and they have been integrating it into their practices. I had a chance in Phoenix, Arizona, just a couple weeks ago at a major lung conference there where I met face-to-face with the head of the valve program, the interventional pulmonology program at Cleveland Clinic.

We discussed, and he said, "They are going to move 100% of their patients from doing nuclear VQ across to CT:VQ." I think that is a pretty fast turnaround to get through, get it installed, get it tested, get it integrated into their workflow, and to have them see it and get so much faith in it that they are willing to turn off the old tech and just move ahead exclusively with our solution.

John Hester
Senior Analyst, Bell Potter Securities

Yes, that is great news. Andreas, there are plenty of algorithms around who claim to add value for interventional pulmonologists. What is your assessment of the rest of the market, and how are you differentiated, do you think?

Andreas Fouras
CEO, 4DMedical

Yeah, I think that there is a few ways that we are different, and they really kind of stack up to be quite significant. I think that, as you say, across medical imaging, and interventional pulmonology is no different, there are in fact lots of algorithm companies out there. Lots of folks who take CAT scans, apply some software, often it is AI, and use that to try to help improve the workflow or improve the efficiency for a doctor. Where they tend to focus is adding value to that CAT scan, that CT scan that lies at the heart of diagnostics in pulmonology today. We have a CT, which is $105 is the Medicare rebate, and you have a bunch of companies out there looking to add value to that CT scan.

As a result, they're hoping to get $1, $2, $12 perhaps at best, by making it more efficient, perhaps making it more accurate, maybe faster, adding to the edges around this $105 value proposition. Where we really focus at 4DMedical is we add value to the procedure. We're adding value to, for example, that $50,000 lung surgery or the $25,000 valve procedure that's put in place. We help identify new patients that wouldn't have been found otherwise.

We do that by showing doctors things that they just can't see. No matter how long they spend looking at the CAT scan, they won't see airflow or blood flow. We show things that wouldn't have been otherwise possible, and we really shift that value paradigm up from, we're not adding value to the $105 CAT scan, we're adding value to the $25,000 procedure that happens after that. We get paid in those kinds of materially bigger terms. We're much more important to these doctors' practices.

John Hester
Senior Analyst, Bell Potter Securities

Okay, let's take a step back. I wanted you to recount a conversation you had at last year's, I think it was at RSNA, it might have been one of the other thoracic society conferences, where a leading clinician came to you and said, "Well, I just don't understand how you can do perfusion, blood flow, without contrast." This is really the secret sauce that 4Dx has. For the benefit of everyone listening in, just take a minute to explain that, and then I want to move on to the CLEAR study, talking about CT:VQ in conventional patients as well.

Andreas Fouras
CEO, 4DMedical

Yeah, it's actually kind of a pretty fun part of the job right now, John, is where we have people still in that really kind of fun stage of, "This is really phenomenal, this is really cool." But sometimes that does get expressed as, "Oh, I don't know, I'm a bit skeptical. I don't know how this is even possible." This is the great thing about us coming at this from a completely different direction than everybody else has come at. In medical imaging, people tend to focus on how bright, these come as black and white images, and brightness and darkness on the image tells you really exactly how dense the thing that you're looking at, that spot. Bones obviously are very dense, they show up differently, lung tissue differently, and air differently on that scale. That's where everybody's come at it from.

4DMedical comes at it from looking at how is the lung tissue moving? How is it working? We start by tracing, first of all, how every single tiny bit of the lung moves from when you breathe in to when you breathe out. We do that with precision and accuracy that nobody else has been able to do before. So now we have that tracking completed. That allows us then to do this next step of doing two things. Number one, how much has every bit of the lung shrunk or expanded? From there, we are able to see how much it should have increased or, if you take a sponge and you stretch it or you compress it, you know that it should get more or less dense by the amount that you squeeze it or stretch it.

We then look at the images, and you can see, guess what? That actually, that does not quite match up. The amount of stretching does not equal how much more or less dense it has got. So now you have this great pretty set of equations which tells you got two things to solve. How much air has gone into that area, how much blood has gone into there, and how much it has shrunk and grown. Actually, that is a closed mathematical problem. We are able to solve that completely. Even more importantly, for the doctors, is we have been able to prove that in case after case after case where we show, firstly, we match things like the nuclear VQ, where we match that. In fact, doctors now learning to trust that where we are different to the nuclear is because we are better.

Even more importantly, they learn to trust it because when they make decisions based on our technology, they get better outcomes for their patients. So, that year of being there in the market, having done hundreds and hundreds of patients and thousands of studies with the clinical research, lays on top of that explanation that now has doctors feeling pretty confident that really is the solution for them.

John Hester
Senior Analyst, Bell Potter Securities

Okay. Just go on and spend a minute or so talking about the CLEAR study, because this is a pretty big one. You have been able to fund this CLEAR study by virtue of that capital raise that happened earlier this year. This is probably the most important study that the company has ever conducted, or certainly one of the most important studies, because it is going to open up a vast commercial opportunity for the company. Just take a minute to talk us through that and Mass General Brigham.

Andreas Fouras
CEO, 4DMedical

Yeah. CT:VQ is a platform, right? That allows us, as I said, to see airflow and blood flow in the lungs.

John Hester
Senior Analyst, Bell Potter Securities

Yeah.

Andreas Fouras
CEO, 4DMedical

Without any contrast agents added. That platform allows us to create multiple markets, multiple business opportunities. The first one being displacing the nuclear VQ test. There's about a million of those a year, and at AUD 500 a test, that's $500 US of opportunity. CLEAR is exciting to us because that means, when we come out with the successful readout from CLEAR, that's going to allow us to then target displacing the CT pulmonary angiogram, the CTPA test. There's 5 million of those a year done in the U.S., and so it's a $2.5 billion opportunity there. In order to take us into that market, doctors make really fast life and death decisions around CTPA.

Our view is that the way to really penetrate that market is, number one, to be successful, to grow in the nuclear space, and then to bring out just overwhelming strength of data. So large, really well-powered, prospective, multicenter study. It's great to have Mass General Brigham, MGB, leading that. That's one of the Harvard set of academic medical centers. They're leading the way as leaders, but also a number of other sites will be coming online in early 2027. So, taking that study to be multicenter. Yeah, so I think bringing that data out there, large volumes of data showing that you can get better outcomes from our technology. In fact, also I need to slightly correct that. All we need to show from the CLEAR study is that you get non-inferior results.

John Hester
Senior Analyst, Bell Potter Securities

Yeah.

Andreas Fouras
CEO, 4DMedical

But I think when we show you get results equally as good, but without having to send someone back to the CT exam and get a new exam, and this time an exam that requires contrast, that's actually the real win. I believe we'll show that you get better results, but we only need to be successful here with this study. It's important that the investment market knows we only need to be non-inferior.

John Hester
Senior Analyst, Bell Potter Securities

I want to switch the focus now onto commercialization, Andreas, and obviously Mass General, a massive hospital up there, hospital system really up there in Massachusetts. What is it going to mean for the hospital from a commercial sense, and how will it increase their top line and make them more profitable? Why is this going to be such an important, I suppose, event, the data from this CLEAR study, in transforming the company in a commercial sense?

Andreas Fouras
CEO, 4DMedical

Yeah, I think we've already had great progress in getting major AMCs to come on board with CT:VQ to replace nuclear VQ.

John Hester
Senior Analyst, Bell Potter Securities

Yeah.

Andreas Fouras
CEO, 4DMedical

We have a pipeline of more AMCs coming in behind that. I guess what I'm saying is we have put our foot out there, we have built that trust in the market for this technology. We do save hospitals time and effort and money by avoiding the nuclear VQ scan. But for somebody who is likely to be in an emergency department, they're getting worked up. In a large number of cases, somewhere post their workup, an emergency doctor is saying to themselves, "Gee, I need to be able to rule out a pulmonary embolism in this patient. But in order to do that right now, I need to send them back to radiology, get a new CAT scan." That CAT scan requires them to have an injection. Now, it's pretty safe. I'm not saying it's not safe, but it's also not without risks.

There's allergic reactions from those iodine injections. There's often iodine shortages. There's a whole range of reasons why there's real risk and real cost to the hospital, and that means they have to have a doctor on standby, on call right there in the radiology department to get that scan done. In emergency rooms across the country, sending somebody out to go to get another scan takes an hour to do that. Sometimes you have to wait for the contrast. Sometimes you have to wait for a doctor to come and be on standby. Then you have to wait for radiology to read that and to read that out. When we can say, "Hey, look, we can run this for you without you having to make the decision about, can we put this patient at risk with the contrast?

Do we have to send another doctor to come down to radiology and delay that process?" represents really significant savings to the hospital. On top of that, still with all of that, 7% of in-hospital deaths in the U.S. are PE-related. We're missing some PEs. One of the reasons we're missing these PEs is because the emergency department have said to themselves, "You know what? It's not really worth me running this test." But when you make the hurdle lower, you make it cheaper and easier and faster to do the test, not only are you saving the hospital money, but you make it easier for them to do these, and you'll miss fewer PEs. Hospitals absolutely don't like people unexpectedly dying in their emergency rooms.

John Hester
Senior Analyst, Bell Potter Securities

Yeah, what a surprise.

Andreas Fouras
CEO, 4DMedical

We can save them money and save them those deaths at the same time. It's a win-win.

John Hester
Senior Analyst, Bell Potter Securities

Yeah. It's certainly a compelling proposition. The SimonMed installation is now complete, and just to explain what that is, SimonMed are one of the very large outpatient radiology imaging providers in the U.S., 170 clinics across multiple states. That business should now be starting to gain some traction. Can you give us an update on how that contract has been progressing?

Andreas Fouras
CEO, 4DMedical

Yeah. We're excited with the partnership. They're great partners. They're working with us really well. The way that SimonMed often operates is that the patient will choose to say, "You know what? I know this form says I should go to this hospital, I should go to this place to get it, but I want to choose, and I want to go to SimonMed," because perhaps it's much more convenient. It's in the community-based system. Also, SimonMed are known to be a little less expensive than a lot of their competitors out there in the market.

It's something that's often driven by the customer or the patient saying, "I want to go to SimonMed." Now that SimonMed can go also to the doctors and say, "Hey, you can save If you don't want to wait seven weeks for your patient to go and do the usual workup for your surgery or your procedure, you want to save weeks off that, if you bring your patient to SimonMed, we can do the CT scan and the VQ component of that all in one hit. We can save you time and money for your practice." Now it allows SimonMed to be able to talk to the doctors with differentiation as well as to the patients with that. That's motivating them to be good partners with us. They're very hungry. They're rapidly growing their business. They're known to be innovators.

As a nice kind of story, when I was in Phoenix, Arizona, which is right in the middle of SimonMed country, the 10 states there, we had a number of doctors saying to us, "Okay, well, when we're at the hospital, we know how to get VQ. If we have in our private practices, can we get VQ there?" When we offered to them and said, "Hey, we just have this new deal with SimonMed," they're like, "Oh, SimonMed, that's great. That's all over. There's SimonMed clinics everywhere. We can easily and comfortably send our patients there. Let us know how to order it." We kept hearing that over and over again from doctors at that conference.

It's very exciting, and just gives us this different avenue to either to allow patients to go outside of the hospital system or for doctors in private practice who are already outside of that system, gives us access to that whole new part of the population.

John Hester
Senior Analyst, Bell Potter Securities

Yeah, it is also worthwhile to mention that they are still very much on the pay-per-scan arrangement for CT:VQ as well. So, whether that is out-of-pocket or otherwise, it is still very much a pay-per-scan arrangement.

Andreas Fouras
CEO, 4DMedical

Yeah. I think as we have said, John, we want to make 2026 about talking about these academic medical centers that we are adding, and we are really not done yet in 2026. I know our folks are starting to wind down, but we are still going to be bringing some new news to the market before the year wraps up, is our expectation. That puts us in this position in calendar 2027, where we can start talking more about scan volume and the growth in that coming through sites like Cleveland Clinic, Stanford University, and of course, that large SimonMed network.

John Hester
Senior Analyst, Bell Potter Securities

Okay. We have just got a couple of minutes left on Drive, and there is quite a few questions coming through asking about financials. For everyone listening, 4DMedical does not provide guidance, never has. Nevertheless, Andreas, lots of questions about when the company is going to achieve break-even and when we can expect some material revenue growth. Perhaps you could make a couple of comments about your expectation for the fourth quarter of 2026, and generally what you see as the direction of the company in terms of financials going into calendar year 2027.

Andreas Fouras
CEO, 4DMedical

Yeah, look, as you say, we do not give that guidance, but we do expect to see, and in fact, really a little ahead of schedule, there is, I think, if you look carefully at the last couple of 4Cs, you can see there is green shoots there in terms of evidence that the revenue is starting to grow. I think we maintain our confidence that over the medium term, over about, say, a five-year period, we expect to really dominate. In fact, we have got a good chance of taking all of those million scans currently delivered by nuclear VQ. I think that means that we absolutely expect to see really significant growth in our revenue in the last two quarters of this year.

Then into the financial year after that, we expect that to continue to grow strongly, and we will have feedback and material growth coming from Europe will start to show up in our revenue numbers in that following financial year, as well as we will start to see perhaps impact from the CLEAR study by that time. I think that in 2028, we really should be on a runway basis getting into that. We should be in the ballpark of break-even by that time.

John Hester
Senior Analyst, Bell Potter Securities

Okay. Andreas, that is a fairly good run through. Obviously, still work on the commercialization piece, but the runway is definitely there. Andreas, that is all we have got time for. Thank you so much for joining us today. We are going to go to a short break, and I think it is going to be Marty back with AYA on the other side of it. Thank you very much.